Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Home > Science Hub > Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
Back to the list

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Download Publication

You might also be interested by

CellTalk

How Does Interim Sample Storage Improve Clinical Trial Outcomes?

May 1, 2023

More info

Infographics

Wondering if the assay you use during your clinical trial is subject to IVD legislation ?

April 13, 2023

More info

Infographics

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

Immune Monitoring

More info

Web News

Simcere Diagnostics and CellCarta Enter Into Strategic Partnership

December 20, 2022

More info